Ring vaginal novaring №1

Active ingredient and dosage form

Vaginal ring:
1 ring contains etonogestrel 11.7 mg, ethinyl estradiol 2.7 mg;
other ingredients: ethylene vinyl acetate copolymer (28% - vinyl acetate); ethylene vinyl acetate copolymer (9% vinyl acetate); Magnesium stearate; purified water;
The ring is packaged in an aluminum foil bag, 1 or 3 bags per pack.

Mechanism of action

Novoring is a hormonal contraceptive for intravaginal administration, containing estrogen - ethinyl estradiol and gestagen - etonogestrel, which releases ethinyl estradiol - 15 mcg / day and etonogestred 120 mcg / day. Etonogestrel, a derivative of 19-nortestosterone, binds to Progesterone receptors in target organs.
The main mechanism of contraceptive action of the drug Novairing is the inhibition of ovulation.

In addition to the contraceptive effect of the drug has a positive effect on the menstrual cycle. Against the background of its use, the cycle becomes more regular, menstruation is less painful, with less intensity of bleeding, which in turn can help reduce the frequency of iron deficiency states. In addition, there is evidence of a reduction in the risk of endometrial cancer and ovarian cancer.

Indications and usage

Intravaginal contraception.

Contraindications

Hypersensitivity to the drug;
venous or arterial thrombosis / thromboembolism (including in the anamnesis);
risk factors for thrombosis (including in history);
migraine with focal neurological symptoms;
diabetic angiopathy;
pancreatitis (including history) in combination with a high degree of hypertriglyceridemia (LDL concentration more than 500 mg / dL);
severe liver disease (until normalization of function indicators);
liver tumors (benign or malignant, including a history);
hormone-dependent malignant tumors (established or suspected, for example, tumors of the genitals or mammary glands);
vaginal bleeding of unknown etiology;
pregnancy or suspicion of it;
lactation period.

WITH caution the drug should be prescribed for diabetes, obesity (body mass index over 30 kg / m2), hypertension, atrial fibrillation, valvular heart disease, dyslipoproteinemia, liver or gall bladder disease, Crohn's disease or ulcerative colitis, sickle cell anemia, SLE, hemolytic uremic syndrome, epilepsy, smoking in combination with the age of more than 35 years, with prolonged immobilization, serious surgical interventions, fibrocystic mastopathy, uterine fibroids, congenital hypothyroidism rbilirubinemiyah (Gilbert syndrome, Dubin-Johnson and Rotor), chloasma (to avoid exposure to UV light), as well as the conditions that make it difficult to use the vaginal ring (cervical prolapse, cystocele, rectocele, severe chronic constipation).

Dosage and administration

Novaring is inserted into the vagina 1 time in 4 weeks. The ring is placed in the vagina for 3 weeks and then removed on the same day of the week in which it was placed in the vagina. After a week break, a new ring is introduced. Bleeding associated with the termination of the drug, usually begins 2-3 days after the removal of NovaRing and may not completely stop until the moment when it is necessary to start using the next ring.

If hormonal contraceptives were not used in the previous menstrual cycle, Novairing should be administered between days 1 and 5 of the menstrual cycle, but no later than the 5th day of the cycle, even if the woman has not completed her menstrual bleeding. During the first 7 days of the first cycle of Novaring, additional use of barrier methods of contraception is recommended.

When switching from taking combined oral contraceptives, Novara should be administered no later than the day following the interval in which the drug is taken. If the combined oral contraceptive also contains an inactive pill (placebo), then NewRing should be administered no later than the day following the last placebo pill.

When switching from progestin contraception (mini-pilli, implant or injection contraception) or progestogen-releasing intrauterine devices (IUD), administration of NovRing should be done on any day (if the patient was taking mini-pili), the next day after removing the implant or IUD, and with injectable contraception - on the day when the next injection is needed.In all these cases, an additional barrier method of contraception should be used during the first 7 days of using Novaring.

Adverse reactions

From the side of the central nervous system: headache, migraine, depression, emotional lability, dizziness, anxiety, fatigue.
From the digestive system: nausea, abdominal pain, diarrhea, vomiting.
On the part of the endocrine system: decrease in libido, soreness, tension and increase in mammary glands, dysmenorrhea, increase or decrease in body weight.
From the reproductive system: vaginal discharge ("whites"), vaginitis, cervicitis.
Urogenital: urinary tract infections (including cystitis).
Local reactions: loss of the ring, discomfort during sexual intercourse in women and men, foreign body sensation in the vagina.
Other: increase or decrease in body weight.

Storage conditions

In the dark place at a temperature of not 2-8 ° C.